U.S. markets closed

Walvax Biotechnology Co., Ltd. (300142.SZ)

Shenzhen - Shenzhen Delayed Price. Currency in CNY
Add to watchlist
43.50+0.50 (+1.16%)
At close: 4:29PM CST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close43.00
Bid43.53 x 0
Ask43.54 x 0
Day's Range42.51 - 44.18
52 Week Range28.80 - 95.90
Avg. Volume66,548,145
Market Cap67.14B
Beta (5Y Monthly)0.68
PE Ratio (TTM)147.46
EPS (TTM)0.29
Earnings DateMar 26, 2021
Forward Dividend & Yield0.02 (0.05%)
Ex-Dividend DateSep 30, 2020
1y Target Est65.34
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      China's Walvax to make COVID-19 vaccine candidate similar to AstraZeneca's - media

      China's Walvax Biotechnology Co has started work on a plant to manufacture an early-stage coronavirus vaccine candidate similar to AstraZeneca PLC's product, state-backed media said on Sunday. Mass production for the proposed vaccine could begin in mid-2021, with an estimated capacity of 200 million doses a year, said Health Times, a paper run by the People's Daily. The treatment is based on a chimpanzee adenovirus to deliver materials that can trigger an immune response against the virus that causes COVID-19, a technique adopted in the candidate from AstraZeneca and Oxford University.

    • Sirnaomics Seals US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections
      PR Newswire

      Sirnaomics Seals US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections

      Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing. This round of funding was co-led by existing investor Rotating Boulder Fund, new investor Walvax Biotechnology Co., Ltd. and Sunshine Riverhead Capital, with support from existing investors Sangel Capital and new investors: Longmen Capital, HongTao Capital and Alpha Win Capital. Chinese Renaissance and Huatai Financial Holdings (Hong Kong) Ltd. served as the financial advisors for this round of fund raising.

    • Reuters

      'One vaccine isn't enough': Mexico aims for its own coronavirus fix

      Mexico is working to produce its own COVID-19 vaccines and could have one ready by next spring, according to a researcher coordinating local efforts amid a global race to tame a disease that has infected over 26.75 million people worldwide. Esther Orozco, coordinator of the scientific group that represents Mexico at the Coalition for Epidemic Preparedness Innovations, said research based on a virus that transmits the avian Newcastle disease is the most viable candidate to produce the first vaccine in Mexico. Orozco said the vaccine, developed by the private firm Laboratorio Avimex with researchers from Mexico's main public university, UNAM, and the Mexican Social Security Institute, is ready to start the first phase of testing with humans.